TB & Outbreaks Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB & Outbreaks Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Biotechnology Business
Cerus Announces Major Presence at Upcoming International Society of Blood Transfusion Conference
April 8th, 2008
Cerus Corporation (NASDAQ: CERS) announced that 32 studies on the company's INTERCEPT Blood System have been accepted for presentation at the International Congress of the International Society of Blood Transfusion to be held in Macao SAR, China, June 7-12, 2008. The studies reported include information on clinical experience from implementation of the INTERCEPT Blood System in routine practice, support of patients with severe congenital bleeding disorders undergoing major surgery, the inactivation of protozoa and Avian influenza virus, patient outcomes from hemovigilence surveillance programs for platelets and plasma, as well as results from clinical studies of the modified red blood cell...
Source: TB & Outbreaks Week (2008-04-08)
|
